ProQR Therapeutics N.V Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-5.6%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$0.71next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly81.1MTarget: Sufficient to fund operations into mid-2027
Quarterly Net Loss Quarterly-13.4MTarget: Minimize cash burn through strategic partnerships
Quarterly R&D Expenses Quarterly11.8MTarget: Maintain disciplined pipeline investment
Watch Items
- AX-0810 Target Engagement DataTrigger: Successful target engagement in healthy volunteers (Q2 2026)Action: Initiate Phase 2 development in biliary atresia and advance investigator-initiated trial (IIT) in China
- AX-0811 Clinical Trial Application (CTA) FilingTrigger: CTA filing in mid-2026Action: Prepare for initial clinical data readout by year-end 2026
- Eli Lilly Collaboration MilestonesTrigger: Execution of research plan and data updates in 2026Action: Recognize milestone payments to extend cash runway beyond mid-2027
Research as of 20 Jun 2026